[1] 王绮夏, 邱德凯, 马雄. 2010年美国肝病学会自身免疫性肝炎指南解读. 中国医学前沿杂志, 2011, 3(8-13).
[2] Yatsuji S, Hashimoto E, Kaneda H, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the international autoimmune hepatitis group scoring system useful?. J Gastroenterol, 2005, 40:1130-1138.
[3] Elalfy H, El-Maksoud MA, Abed S, et al. Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease. Br J Biomed Sci, 2019, 76:101-103.
[4] Matsumoto T, Yamasaki S, Arakawa A, et al. Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. Pathol Int, 2007, 57:388-389.
[5] Salmon C, Hoeroldt B, Dube A, et al.1115 Hepatic steatosis in patients with autoimmune hepatisis (AIH)-prevalence, progression and possible significance.J Hepatol, 2010, 52.
[6] Shimizu H, Shimizu T, Takahashi D, et al. Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report.BMC Musculoskelet Disord, 2019, 20:88.
[7] De Luca-Johnson J, Wangensteen KJ, Hanson J, et al. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Dig Dis Sci, 2016, 61:2710-2720.
[8] 周光德, 赵景民. 不同病因致肝纤维化/肝硬化的病理特点. 临床肝胆病杂志, 2016, 32:1086-1091.
[9] 王泰龄, 赵新颜. 自身免疫性肝炎的病理特点, 2011.
[10] Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol, 2014, 20:15539-15548.
[11] Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology, 1990, 11:74-80.
[12] Dalekos GN, Gatselis NK, Zachou K, et al. NAFLD and autoimmune hepatitis: do not judge a book by its cover. Eur J Intern Med, 2020, 75:1-9. |
